On August 28, 2026, the clinical trial registry listed an update for a Phase 3 study involving octreotide acetate. The trial, titled "Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor," is registered under identifier NCT00569127.
The study's current status is active, not recruiting, meaning enrollment has closed but participant follow-up or trial activities are ongoing. It is designated as a Phase 3 trial, evaluating octreotide acetate in combination with either recombinant interferon alfa-2b or bevacizumab in patients with metastatic or locally advanced, high-risk neuroendocrine tumors.
This update reflects only the trial's registration status as of the listed date. No outcome data, efficacy results, or safety findings are included in this status update. The trial's design continues to focus on this specific patient population and treatment combination as originally registered.
Readers interested in additional information can consult the trial registry directly for further details on the study protocol and any future updates. For general background on octreotide, its approved uses, and related regulatory information, readers can refer to the compound overview.